Tzu-Fei Wang: Drug–Drug Interactions Between DOACs and Prostate Cancer Therapies
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Cancer, adding:
“Concerned about drug – drug interactions between DOACs and prostate cancer therapies?
New study of 2,297 patients from Ontario and Alberta:
No increase in thrombosis with DOACs and enzalutamide or apalutamide
No increase in bleeding with DOAC and abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont , Cynthia Wu , Pietro Ravani , Dominick Bossé , Robert Talarico, Marc Carrier , Manish M. Sood
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 11, 2026, 05:11Daniel I McIsaac: Less Blood Loss and No Excess VTE with Tranexamic Acid in High-Risk Surgery
-
Jun 11, 2026, 05:03Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
-
Jun 11, 2026, 04:53Umut Kocabas: Current Practice and Guideline Adherence on Cancer-Associated Thrombosis in Turkey
-
Jun 11, 2026, 04:40Fernanda Orsi: Which Obstetric APS Patients Are More Likely to Develop Thromboses?
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation